AAD 2026: New Oral Therapies & Guidelines for Dermatologists

The landscape of psoriasis treatment is shifting, with a notable focus on the development of effective oral therapies. Discussions at recent dermatology conferences, including Maui Derm 2026 and the upcoming American Academy of Dermatology (AAD) 2026 meeting in Denver, are highlighting these advancements and potential new guidelines. Dr. James Song, Co-CMO, has been central to these conversations, outlining a pipeline of oral treatments that may soon rival existing biologic therapies in their efficacy.

Oral Therapies: A Potential Game Changer

For years, systemic biologic therapies have been the gold standard for moderate to severe psoriasis, offering significant improvements for many patients. However, these treatments typically require injections or infusions, which can present logistical challenges and may not be suitable for everyone. Oral therapies, taken as pills, offer a more convenient administration route. Historically, their effectiveness hasn’t consistently matched that of biologics, but that appears to be changing. Recent discussions suggest that new oral therapies in development are demonstrating promising results, potentially offering comparable efficacy to their injectable counterparts.

Dr. Song’s presentation at Maui Derm 2026 and subsequent discussions, focused on the therapies currently in the pipeline. While specific details about these therapies remain largely within the research and development phase, the overall trend points towards more targeted and potent oral medications. This is particularly significant as it expands treatment options for individuals who may not respond well to, or cannot tolerate, biologic therapies.

What is Psoriasis?

Psoriasis is a chronic autoimmune disease that affects the skin. It causes skin cells to multiply too quickly, resulting in thick, red, scaly patches. These patches can be itchy, painful, and disfiguring. While psoriasis is a skin condition, it’s also linked to other health problems, including psoriatic arthritis, heart disease, and metabolic syndrome. The severity of psoriasis varies greatly from person to person.

AAD 2026: A Showcase for Innovation

The AAD 2026 conference in Denver is expected to be a key venue for showcasing these emerging oral therapies and discussing updated treatment guidelines. The conference will likely address not only the efficacy of these new treatments but also their safety profiles and optimal use in combination with other therapies. The focus extends beyond simply addressing skin symptoms; the conference will also explore approaches to manage the broader health challenges faced by psoriasis patients.

Understanding the Pipeline: What’s Being Developed?

While specific details are still emerging, the therapies in the pipeline are believed to target different pathways involved in the inflammatory process that drives psoriasis. This includes exploring new mechanisms of action and refining existing ones to improve efficacy and reduce side effects. The goal is to develop oral medications that can effectively control psoriasis symptoms with a more convenient and tolerable treatment regimen.

The development of these oral therapies is also being informed by a growing understanding of the genetic and immunological factors that contribute to psoriasis. This allows researchers to design more targeted therapies that address the underlying causes of the disease, rather than simply suppressing the symptoms.

What Does This Mean for Patients?

The potential availability of more effective oral therapies could significantly improve the quality of life for individuals living with psoriasis. A convenient oral medication could offer a viable alternative for those who are hesitant to start or continue biologic therapies due to injection-related anxiety or logistical difficulties. It also provides additional options for patients whose psoriasis doesn’t respond adequately to existing treatments.

However, it’s important to remember that these therapies are still under development and have not yet been approved for widespread use. Clinical trials are ongoing to evaluate their safety and efficacy, and it will take time for these medications to become available to patients.

The Role of Guidelines and Combination Approaches

Alongside the development of new therapies, updated treatment guidelines are also expected to be highlighted at AAD 2026. These guidelines will likely emphasize a more personalized approach to psoriasis management, taking into account the individual patient’s disease severity, comorbidities, and treatment preferences. The guidelines may also address the use of combination therapies, where different treatments are used together to achieve better results. This could involve combining oral therapies with topical treatments or biologics, depending on the individual patient’s needs.

Looking Ahead: Ongoing Research and Surveillance

The field of psoriasis treatment is constantly evolving. Ongoing research is focused on identifying new therapeutic targets, developing more effective delivery systems, and understanding the long-term effects of different treatments. Post-market surveillance will also be crucial to monitor the safety and efficacy of these new oral therapies once they become available to a wider patient population. This surveillance will help identify any potential side effects or unexpected outcomes and inform future treatment decisions.

For individuals with psoriasis, staying informed about the latest advancements and discussing treatment options with a qualified dermatologist is essential. Regular check-ups and adherence to a personalized treatment plan can help manage symptoms and improve overall quality of life.